WAVE Life Sciences(WVE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

WVE WAVE Life Sciences

Trading 01-21 12:12:54 EST

13.61

-0.21

-1.52%

High14.48	Low13.61	Vol1.22M
Open13.81	D1 Closing13.82	Amplitude6.30%
Mkt Cap2.49B	Tradable Cap2.15B	Total Shares182.97M
T/O17.10M	T/O Rate0.77%	Tradable Shares157.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"WVE","market":"US","secType":"STK","nameCN":"WAVE Life Sciences","latestPrice":13.61,"timestamp":1769015573925,"preClose":13.82,"halted":0,"volume":1215397,"delay":0,"changeRate":-0.0151953690303908,"floatShares":157870759,"shares":182971259,"eps":-0.743552,"marketStatus":"Trading","change":-0.21,"latestTime":"01-21 12:12:54 EST","open":13.805,"high":14.48,"low":13.61,"amount":17101820.802075002,"amplitude":0.062952,"askPrice":13.63,"askSize":8,"bidPrice":13.61,"bidSize":93,"shortable":3,"etf":0,"ttmEps":-0.743552,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769029200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1447218000000,"exchange":"NASDAQ","adjPreClose":13.82,"preHourTrading":{"tag":"盘前","latestPrice":13.57,"preClose":13.82,"latestTime":"09:29 EST","volume":3331,"amount":45874.06566,"timestamp":1769005799999,"change":-0.25,"changeRate":-0.01809,"amplitude":0.040521},"postHourTrading":{"tag":"盘后","latestPrice":13.8632,"preClose":13.82,"latestTime":"19:37 EST","volume":43189,"amount":597109.9777,"timestamp":1768955821914,"change":0.0432,"changeRate":0.003126,"amplitude":0.016643},"volumeRatio":0.733189,"impliedVol":0.8142,"impliedVolPercentile":0.3147},"requestUrl":"/m/hq/s/WVE/tweets","defaultTab":"tweets","newsList":[{"id":"2603544003","title":"Wave Life Sciences Reports $602 Million Year-End Cash Position and Outlines 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2603544003","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603544003?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:25","pubTimestamp":1768235158,"startTime":"0","endTime":"0","summary":"Wave Life Sciences Ltd. announced a preliminary, unaudited cash and cash equivalents position of approximately $602 million as of December 31, 2025, with an expected cash runway extending into the third quarter of 2028. These results are subject to adjustment, and the company plans to report its final fourth-quarter and full-year 2025 financial results in late February 2026. The company also outlined strategic priorities for 2026, including the acceleration of development for WVE-007, an investigational INHBE GalNAc-siRNA for obesity. Initial data from a 240 mg single-dose of WVE-007 reported in 2025 showed improved body composition with fat loss similar to GLP-1 at three months, muscle preservation, and the potential for once or twice-yearly dosing. Wave expects to begin a Phase 2a multidose portion of the WVE-007 INLIGHT clinical trial in individuals with obesity in the first half of 2026, and to initiate new trials evaluating WVE-007 as an add-on to incretin therapy and as a post-in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6Rn7Bc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2602517086","title":"Wave Life Sciences highlights priorities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517086?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:56","pubTimestamp":1768222561,"startTime":"0","endTime":"0","summary":"Wave Life Sciences (WVE) highlighted its strategic priorities for 2026. Key highlights include: Wave expects to initiate a Phase 2a multidose porti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-highlights-priorities-for-2026-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-highlights-priorities-for-2026-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2602512475","title":"Wave Life Sciences Presents at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512475?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221015,"startTime":"0","endTime":"0","summary":"Wave Life Sciences Ltd. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, where President and CEO Paul Bolno presented the company’s 2026 strategic priorities. Highlights included plans to accelerate the development of WVE-007, an investigational INHBE GalNAc-siRNA for obesity, and further advance its RNA editing portfolio. The company also outlined its intention to begin new clinical trials for WVE-007 and to file regulatory applications for additional programs in the coming year. The presentation was webcast live and is available for replay on the company’s investor relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL45w0Fc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","BK4007","NDAQ","LU2095319765.USD","BK4588","WVE"],"gpt_icon":0},{"id":"2602512739","title":"Wave Life Sciences: Expects to File Cta in 2026 for Wve-008 in U.S. and Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512739","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512739?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7GKQNG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2602512722","title":"Wave Life Sciences : Remains on Track to File Nda in 2026 to Support Accelerated Approval of Wve-N531 With Monthly Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512722?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7GKQNG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2602051219","title":"Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44TH Annual J.p. Morgan Healthcare Conference: Accelerating Development of Wve-007 (Inhbe Sirna) for Obesity and Rapidly Advancing Rna Editing Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2602051219","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602051219?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7GKQNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WVE","BK4007"],"gpt_icon":0},{"id":"2601828878","title":"Wave Life Sciences Officer Chris Francis Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828878","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828878?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:30","pubTimestamp":1767753039,"startTime":"0","endTime":"0","summary":"Chris Francis, an officer of Wave Life Sciences Ltd., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLPzMr0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Wave Life Sciences Officer Chris Francis Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WVE","BK4007"],"gpt_icon":0},{"id":"2601819027","title":"Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2601819027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601819027?lang=en_us&edition=fundamental","pubTime":"2026-01-07 00:26","pubTimestamp":1767716760,"startTime":"0","endTime":"0","summary":"An experimental drug from the biotech Arrowhead Pharmaceuticals helped patients on Eli Lilly's Zepbound lose even more weight in a clinical trial, but big questions remain about how much patients will care.Arrowhead said that patients on its drug ARO-INHBE and Zepbound lost an average of 9.4% of their weight after 16 weeks, compared with a 4.8% weight loss in patients on Zepbound alone.The early-stage Phase 1/2 trial tested the drug in obese patients with type 2 diabetes, who generally lose less weight on medicines like Zepbound than patients who do not have the condition.Arrowhead shares were up 17.6% Tuesday, after falling 5.7% Monday amid a broader pullback in biotech stocks.It's all part of the next phase of the obesity market, created over the past few years by the arrival of Novo Nordisk's Wegovy and Lilly's Zepbound. Together, the two drugs have created a massive new market for obesity treatments, with sales of Zepbound alone expected to have surpassed $13 billion in 2025, accor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2471134879.HKD","LU2491050154.USD","SG9999015952.SGD","SGXZ81514606.USD","IE00BK4W5M84.HKD","LU1064131342.USD","LU0323591593.USD","LU2089984988.USD","LU2108987350.USD","LU0820561909.HKD","LU0787776722.HKD","LU0122379950.USD","LU0109391861.USD","WVE","LU1917777945.USD","LLY","LU1868837136.USD","BK4599","LU1868837300.USD","LU1127390331.HKD","SG9999013999.USD","BK4581","LU0198837287.USD","LU1057294990.SGD","IE00BJJMRX11.SGD","IE00BZ1G4Q59.USD","LU0354030511.USD","LU0058720904.USD","LU1974910355.USD","LU2552382215.SGD","LU0256863902.USD","LU2237438978.USD","LU2461242641.AUD","SG9999015986.USD","IE00BKVL7J92.USD","LU0786609619.USD","LU0234572021.USD","LU2237443622.USD","SG9999014880.SGD","SG9999001176.SGD","SG9999014906.USD","IE00B1XK9C88.USD","LU2168564065.EUR","LU0154236417.USD","LU1023059063.AUD","LU1366192091.USD","IE00BFTCPJ56.SGD","LU0672654240.SGD","ARWR"],"gpt_icon":1},{"id":"2594282034","title":"Wave Life Sciences (WVE) Is Up 11.7% After Early WVE-007 Fat-Loss Data - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2594282034","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594282034?lang=en_us&edition=fundamental","pubTime":"2025-12-25 10:45","pubTimestamp":1766630739,"startTime":"0","endTime":"0","summary":"In December 2025, Wave Life Sciences reported interim Phase 1 INLIGHT data for its investigational siRNA therapy WVE-007, showing meaningful reductions in visceral and total body fat and increases in lean mass after a single 240 mg dose in metabolic disease patients.\nBecause WVE-007’s early results suggest simultaneous fat loss and lean mass preservation, it may address an important limitation of many existing obesity treatments.\nNext, we’ll explore how this early WVE-007 efficacy and safety...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-117-after-early-wve-007-fat-los","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-117-after-early-wve-007-fat-los","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["WVE","BK4007"],"gpt_icon":0},{"id":"2592919694","title":"Wave Life Sciences Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2592919694","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592919694?lang=en_us&edition=fundamental","pubTime":"2025-12-20 00:30","pubTimestamp":1766161800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/WVE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2025 11:30 ET (16:30 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2592195567","title":"Wave Life Sciences Ltd. : H.c. Wainwright Raises Target Price to $30 From $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2592195567","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592195567?lang=en_us&edition=fundamental","pubTime":"2025-12-19 23:35","pubTimestamp":1766158534,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nAZN4RH4QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2592594908","title":"From on-device AI to the 'girlfriend index,' trading ideas from the research firm that nailed 2025's investment themes","url":"https://stock-news.laohu8.com/highlight/detail?id=2592594908","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592594908?lang=en_us&edition=fundamental","pubTime":"2025-12-18 19:52","pubTimestamp":1766058720,"startTime":"0","endTime":"0","summary":"Citrini Research urges investors to stay open-minded in the year ahead. Citrini Research says companies aren't getting enough credit by investors for shaving jobs.Be open to \"maybe,\" says a research firm whose founder who nailed diet drugs and AI themes early.\"While there's a laundry list of things I wish I had done differently since the market bottomed in October 2022, I know that the only reason I've more than tripled my money since then is because I was open to maybe,\" says Citrini Research in its just-released trades for 2026. \"Maybe the hyperscalers will actually be fine if rates are higher for longer. Maybe AI isn't the next fad investors immediately get burned on.\". Here are some of Citrini's 26 ideas for 2026, starting with a basket of companies overlooked in the rush to invest in big AI players.\"If 2026 is the year we see AI-driven head count reductions and productivity gains, one might expect that there would be some degree of anticipation of this AI-shift in the share price ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1506573853.SGD","OMC","AI","BK4533","LU0096364046.USD","LU0348723411.USD","ONDS","AS","MOH","AVY","BAH","QCOM","WVE","LU0231203729.USD","LU0256863811.USD","SG9999018865.SGD","WPP","IE00B775H168.HKD","TSLA","MACW.SI","TSYW.SI","HPQ","DELL","KTOS","GIB","BP","NXST","ADI","BK4534","CRSR","LU2083900584.USD","LULU","ALNY","MU","LU0234570918.USD","LU1301847155.USD","LU0203201768.USD","SBGI","LU0385154629.USD","IBM","SG9999002224.SGD","CTSH","AAPL","TGNA","RL","BK4598","OSCR","ARWR","LLY","CNC"],"gpt_icon":0},{"id":"2591982330","title":"Wave Life Sciences Ltd. : Oppenheimer Raises Target Price to $32 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591982330?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:09","pubTimestamp":1765890583,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"734f4b0bfdb9d119a1a8642d9e1d5f50","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nAZN4RG0TU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2591982780","title":"Subdued Growth No Barrier To Wave Life Sciences Ltd. (NASDAQ:WVE) With Shares Advancing 128%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591982780","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591982780?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:02","pubTimestamp":1765890122,"startTime":"0","endTime":"0","summary":"The Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has done very well over the last month, posting an excellent...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/subdued-growth-no-barrier-to-wave-life-sciences-ltd-nasdaqwv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/subdued-growth-no-barrier-to-wave-life-sciences-ltd-nasdaqwv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SQQQ","WVE","USJW.SI","TSYW.SI",".IXIC","QLD","USAW.SI","PSQ","NVIW.SI","QID","TQQQ","NQmain","MNQmain","BK4007"],"gpt_icon":1},{"id":"2591233624","title":"GSK plc Reports Acquisition of Common Shares in Wave Life Sciences Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2591233624","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591233624?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:32","pubTimestamp":1765834351,"startTime":"0","endTime":"0","summary":"GSK plc has reported an acquisition of common shares of Wave Life Sciences Ltd., according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL15jlhC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","LU1202635105.USD","LU0971552830.HKD","LU1046248800.SGD","LU0203345920.USD","LU0058720904.USD","LU1645745479.HKD","LU1481599808.USD","LU1400636574.HKD","LU0225771236.USD","LU1228905540.USD","LU0225284248.USD","LU0545562505.USD","LU1228905037.USD","BK5011","LU0321505439.SGD","BK4007","LU1302929846.USD","LU1400636491.USD","LU1670756490.USD","IE00B3T34201.USD","LU0306807586.USD","LU0971552673.USD","LU1400636657.SGD","IE0034235071.USD","LU0321505868.SGD","LU1481600234.SGD","LU0109981661.USD","IE00BWDBJ516.SGD","LU0289739699.SGD","LU1487256676.USD","IE00BQJZX424.USD","LU1015430645.USD","LU1098665638.USD","LU1064927863.SGD","LU0575583348.USD","LU1309081286.SGD","WVE","LU0161305163.EUR","GSK.UK","LU1035777561.USD","LU0211331839.USD","LU0985481810.HKD","LU0306806265.USD"],"gpt_icon":1},{"id":"2591462900","title":"Wave Life Sciences' Obesity Drug Shows Promise for Long-Term Growth, Truist Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2591462900","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591462900?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:27","pubTimestamp":1765830478,"startTime":"0","endTime":"0","summary":"Wave Life Sciences'  positive phase 1 data on experimental obesity drug WVE-007 suggests a higher earnings potential with a possible 2029 launch in the best-case scenario, Truist said Monday in a note.The drug may reach $10 billion in cumulative US sales by 2043, depending on trial outcomes and possible label expansion, Truist said.The firm assigns a 25% probability of success and projects initial pricing around $25,000 per year, adjusted for inflation.A commercial launch would likely follow two 72-week phase 3 trials, though a single trial may suffice pending guidance from the US Food and Drug Administration, Truist said.WVE-007 targets the INHBE gene and may offer metabolic benefits beyond standard weight-loss effects, the report said.Wave's stereopure siRNA platform shows a strong competitive edge following four straight successful data readouts, the report said.Truist raised its price target on Wave stock to $50 from $36 and maintained its buy rating.Price: 16.24, Change: -0.32, Pe","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d9195e547cd54787a79fd220bebc4fcb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","WVE"],"gpt_icon":1},{"id":"2591478596","title":"Wave Life Sciences Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2591478596","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591478596?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:46","pubTimestamp":1765809960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/WVE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 09:46 ET (14:46 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d9195e547cd54787a79fd220bebc4fcb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WVE","BK4007"],"gpt_icon":0},{"id":"2591493536","title":"Truist Raises Price Target on Wave Life Sciences to $50 From $36, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2591493536","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591493536?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:58","pubTimestamp":1765803514,"startTime":"0","endTime":"0","summary":"Wave Life Sciences (WVE) has an average rating of buy and mean price target of $31.56, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d9195e547cd54787a79fd220bebc4fcb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2591364615","title":"Wave Life Sciences Ltd : Truist Securities Raises Target Price to $50 From $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2591364615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591364615?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:38","pubTimestamp":1765802301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d9195e547cd54787a79fd220bebc4fcb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WVE","BK4007"],"gpt_icon":0},{"id":"2590507751","title":"Wave Life Sciences' Robust 2026 Pipeline to Support Outlook, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590507751","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590507751?lang=en_us&edition=fundamental","pubTime":"2025-12-12 23:25","pubTimestamp":1765553109,"startTime":"0","endTime":"0","summary":"Wave Life Sciences'  PRISM technology platform is expected to support a robust pipeline for 2026 and its outlook, Wedbush said in a note Friday, adding the stock to its \"Best Ideas List.\"The upcoming WVE-007 higher-dose readouts in Q1 and Q2 2026, a WVE-006 update in alpha-1 antitrypsin deficiency in Q1 2026, and an expected New Drug Application submission for WVE-N531 in Duchenne muscular dystrophy, are expected to support the company's numbers going forward, the investment firm said.Wedbush said it raised its probability-of-success estimate for WVE-007 to 50% from 25% and models it as a potential monotherapy in obesity in addition to an add-on approach with GLP-1 therapies.Wedbush's 2035 worldwide revenue view for WVE-007 is $8.3 billion across monotherapy and add-on use, up from a prior $2.5 billion estimate focused on add-on use alone, according to the note.WVE-006 is also part of the company's broader validation case for Wave's RNA editing approach, including a possible 2026 clini","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d86fc1a050ef35f0b0e63806145f697e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WVE","BK4007"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.wavelifesciences.com","stockEarnings":[{"period":"1week","weight":-0.0281},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.9248},{"period":"6month","weight":0.6472},{"period":"1year","weight":0.2575},{"period":"ytd","weight":-0.1871}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.076645},{"month":2,"riseRate":0.7,"avgChangeRate":0.067262},{"month":3,"riseRate":0.3,"avgChangeRate":-0.085138},{"month":4,"riseRate":0.2,"avgChangeRate":-0.079373},{"month":5,"riseRate":0.5,"avgChangeRate":0.001154},{"month":6,"riseRate":0.5,"avgChangeRate":0.136995},{"month":7,"riseRate":0.5,"avgChangeRate":0.010097},{"month":8,"riseRate":0.8,"avgChangeRate":0.166322},{"month":9,"riseRate":0.4,"avgChangeRate":0.023822},{"month":10,"riseRate":0.5,"avgChangeRate":0.114526},{"month":11,"riseRate":0.6,"avgChangeRate":0.099642},{"month":12,"riseRate":0.181818,"avgChangeRate":0.00812}],"exchange":"NASDAQ","name":"WAVE Life Sciences","nameEN":"WAVE Life Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"WAVE Life Sciences(WVE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest WAVE Life Sciences(WVE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"WAVE Life Sciences,WVE,WAVE Life Sciences股票,WAVE Life Sciences股票老虎,WAVE Life Sciences股票老虎国际,WAVE Life Sciences行情,WAVE Life Sciences股票行情,WAVE Life Sciences股价,WAVE Life Sciences股市,WAVE Life Sciences股票价格,WAVE Life Sciences股票交易,WAVE Life Sciences股票购买,WAVE Life Sciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"WAVE Life Sciences(WVE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest WAVE Life Sciences(WVE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction